

Clinical Policy: Hyperhidrosis Treatments

Reference Number: CP.MP.62

Last Review Date: 01/21

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Hyperhidrosis is defined as excessive sweating beyond a level required to maintain normal body temperature in response to heat exposure or exercise.

Refer to CP.PHAR.09 Botulinum Toxins for requests for Botox or Dysport.

Refer to CP.PMN.117 Qbrexza (glycopyrronium) for requests for glycopyrronium

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that treatment with iontophoresis (electrophoresis, Drionic device) is **medically necessary** when *all* of the following criteria are met:
 - A. Diagnosis of primary hyperhidrosis;
 - B. Member has developed medical complications, such as skin maceration with secondary skin infections; *or* has a significant constant disruption of professional and/or social life (e.g., recurrent changing of clothes, affecting job/social function, etc.) which has occurred because of excessive sweating;
 - C. Is unresponsive or unable to tolerate at least one of the pharmacotherapies prescribed for excessive sweating (e.g., anticholinergics, beta-blockers, or benzodiazepines);
 - D. Failed a 6-month trial of conservative management including the adherent application of aluminum chloride hexahydrate [Drysol by prescription] or topical agents have resulted in a severe rash;
 - E. Has none of the following contraindications:
 1. Cardiac pacemaker;
 2. Cardiac arrhythmias;
 3. Pregnancy (hyperhidrosis often improves during pregnancy);
 4. Metal implants, depending on size and position (may divert the electric current);
 5. Cracked skin near the treatment area.

- II. It is the policy of health plans affiliated with Centene Corporation® that endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis is **medically necessary** when *all* of the following criteria are met:
 - A. Meets all of the iontophoresis criteria in I.A-D;
 - B. Has a resting heart rate ≥ 55 beats per minute;
 - C. Hyperhidrosis symptoms started at an early age (usually < 16 years), and surgery is requested for a young member (usually < 25 years of age);
 - D. Body mass index < 28 ;
 - E. Reports no sweating during sleep;
 - F. The member is relatively healthy with no significant comorbidities;
 - G. Has persistent and severe primary hyperhidrosis;
 - H. Has failed one of the following:

CLINICAL POLICY

Hyperhidrosis Treatments

1. Iontophoresis;
2. Trial of botulinum toxin for predominantly axillary hyperhidrosis.

III. It is the policy of health plans affiliated with Centene Corporation[®] that surgical excision of axillary sweat glands for axillary hyperhidrosis are **medically necessary** when *all* of the following criteria are met:

- A. Meets all of the iontophoresis criteria in I.A-D;
- B. Has persistent and severe primary hyperhidrosis;
- C. Has failed one of the following:
 1. Iontophoresis;
 2. Trial of botulinum toxin.

Note: The normal line of medical therapy is:

1. Drysol, then botox or topical glycopyrronium for axillary hyperhidrosis
2. Drysol, then iontophoresis for palmoplantar hyperhidrosis
3. Other treatments are third-line therapies (iontophoresis and surgery for axillary hyperhidrosis, and Botox and surgery for palmoplantar hyperhidrosis).

IV. All other treatments for hyperhidrosis, including, but not limited to, microwave therapy, or liposuction as the sole method of removing axillary sweat glands, are considered **investigational and not medically necessary**.

Background

Hyperhidrosis can be classified as either primary or secondary. Primary focal hyperhidrosis is idiopathic in nature and is defined as excessive sweating induced by sympathetic hyperactivity in selected areas that is not associated with an underlying disease process. The most common locations are underarms (axillary hyperhidrosis), hands (palmar hyperhidrosis), and feet (plantar hyperhidrosis). Primary focal hyperhidrosis is a condition that is characterized by visible, excessive sweating of at least 6 months' duration without apparent cause. Hyperhidrosis can ruin clothing, produce emotional distress, and lead to occupational disability.

Secondary hyperhidrosis can result from a variety of drugs, such as tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), or underlying diseases/conditions, such as febrile diseases, diabetes mellitus, or menopause. Secondary hyperhidrosis is usually generalized or craniofacial sweating. Secondary gustatory hyperhidrosis is excessive sweating on ingesting highly spiced foods. This trigeminovascular reflex typically occurs symmetrically on scalp or face and predominately over forehead, lips, and nose. Secondary facial gustatory sweating, in contrast, is usually asymmetrical and occurs independently of the nature of the ingested food. This phenomenon frequently occurs after injury or surgery in the region of the parotid gland.

A variety of therapies have been investigated for primary hyperhidrosis, including topical therapy with aluminum chloride, iontophoresis, intradermal injections of botulinum toxin type A, endoscopic transthoracic sympathectomy, and surgical excision of axillary sweat glands. Thoracic sympathectomy is an invasive procedure intended to arrest the symptoms of hyperhidrosis. Treatment of secondary hyperhidrosis focuses on the treatment of the underlying

CLINICAL POLICY

Hyperhidrosis Treatments

cause, such as discontinuing certain drugs or hormone replacement therapy as a treatment of menopausal symptoms.

Microwave energy has been proposed for the treatment of primary axillary hyperhidrosis. The miraDry System (Mirimar Labs, Inc) is an FDA approved device indicated for treatment of primary axillary hyperhidrosis. It is not indicated for treating hyperhidrosis related to other body areas or generalized hyperhidrosis. The evidence supporting the safety and efficacy of microwave energy for the treatment of primary axillary hyperhidrosis is limited, thus it is considered investigational and not medically necessary. Most of the studies are limited by small sample size with data on long-term health outcomes lacking.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair
15877*	Suction assisted lipectomy; trunk
15878*	Suction assisted lipectomy; upper extremity
32664	Thoracoscopy, surgical; with thoracic sympathectomy
64802 – 64823	Sympathectomy, sympathetic nerves
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave)
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

* Considered investigational, not medically necessary when used to report liposuction as the sole method of removing axillary sweat glands.

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
L74.510-L74.519	Primary focal hyperhidrosis
L74.52	Secondary hyperhidrosis
R61	Generalized hyperhidrosis

CLINICAL POLICY
Hyperhidrosis Treatments

Reviews, Revisions, and Approvals	Date	Approval Date
Policy Developed Specialist review	04/13	05/13
Removed all surgical treatments except ETS and excision of sweat glands Updated coding implications	04/14	05/14
Removed Botox and Dysport from policy, refer to CP.PHAR.09 Botulinum Toxins	04/15	04/15
Policy converted to new template References reviewed and updated	04/16	04/16
Added microwave therapy for treatment of hyperhidrosis as investigational. Specified in I.A. and II.B. that diagnosis must be primary hyperhidrosis. References reviewed and updated. ICD 10 codes added.	04/17	04/17
Changed I.B from “job/social promotion” to “job/social function.” References reviewed and updated.	02/18	02/18
Separated criteria for ETS and removal of axillary sweat glands, and specified that they meet criteria for iontophoresis A-D. For ETS, added criteria that member heart rate is ≥ 55 beats per minute, symptoms started before 16 years of age, and surgery is on a member less than 25 years of age, that there be no significant comorbidities, that there is no night sweating, and BMI < 28, per 2011 guidelines.	06/18	06/18
Added topical glycopyrronium to normal line of medical therapy for axillary hyperhidrosis, in the note under III. References reviewed and updated.	01/19	02/19
Removed informational codes for chemical denervation of sweat glands: 64560, 64563. Added codes 11450 and 11451.	11/19	
Section IV: Added liposuction as the sole method of removing axillary sweat glands as investigational. Specialist reviewed.	12/19	01/20
Combined criteria points in II. H. and III. C to read “failed one of the following: 1. Iontophoresis or 2. Trial of botulinum toxin.” References reviewed and updated. Replaced “members” with “members/enrollees” in all instances.	12/20	01/21

References

1. Cerfolio RJ, De Campos JR, Bryant AS, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. *Ann Thorac Surg.* 2011;91(5):1642-1648
2. Eisenach JH, Atkinson JL, Fealey RD. Hyperhidrosis: Evolving therapies for a well-established phenomenon. *Mayo Clin Proc.* 2005;80(5):657-666.
3. Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. *Neurotox Res.* 2006;9(2-3):173-177.
4. Glaser DA, Coleman WP 3rd, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. *Dermatol Surg* 2012; 38:185
5. Hong HC, Lupin M, O’Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. *Dermatol Surg* 2012; 38:728.

CLINICAL POLICY**Hyperhidrosis Treatments**

6. Hsu TH, Chen YT, Tu YK, Li CN. A systematic review of microwave-based therapy for axillary hyperhidrosis. *J Cosmet Laser Ther.* 2017 Mar 10.
7. International Hyperhidrosis Society. Hyperhidrosis Treatment Overview. 2017. Available at: <http://www.sweathelp.org/en/hyperhidrosis-treatments/treatment-overview.html>.
8. Karpinski RHS. Surgical treatment of axillary hyperhidrosis treatment & management. In: *Medscape Reference, Caputy G (Ed),* 2012 Jan 31.
9. Lakraj, A.D; Moghimi, N; Jabbari, B. Hyperhidrosis: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins. *Toxins* 2013, 5, 821-840; doi:10.3390/toxins5040821.
10. New Zealand Dermatology Society Inc. Hyperhidrosis. *DermNet NZ [website] Auckland, NZ: NZDS* 2015. Available at: <http://www.dermnetnz.org/hair-nails-sweat/hyperhidrosis.html>.
11. New Zealand Dermatology Society Inc. Iontophoresis. *DermNet NZ [website] Auckland, NZ: NZDS* 2013. Available at: <http://www.dermnetnz.org/procedures/iontophoresis.html>.
12. Smith CC, Pariser, D. Primary focal hyperhidrosis. In: *UpToDate, Dellavalle RP, Dahl MV (Ed), UpToDate, Waltham, MA.* Accessed December 17, 2020.
13. Pariser DM, Hebert AA, Drew J, et al. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. *Am J Clin Dermatol.* 2018 Oct 30. doi: 10.1007/s40257-018-0395-0. [Epub ahead of print]
14. Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. *J Am Acad Dermatol.* 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10.
15. Sheikh NK, Dua A. Iontophoresis Analgesic Medications. <https://www.ncbi.nlm.nih.gov/books/NBK553090/>. [Updated 2020 Oct 11]. Published January 2020. Accessed December 21, 2020.
16. Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. *J Thorac Dis.* 2017;9(Suppl 3):S178-S192. doi:10.21037/jtd.2017.04.04

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits

CLINICAL POLICY

Hyperhidrosis Treatments

are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.